Product Description
Mechanisms of Action: ADRB Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Chile | Hong Kong | Ireland | Korea | New Zealand | Peru | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: Shanghai Changzheng Hospital
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2400081693 |
ChiCTR2400081693 | N/A |
Not yet recruiting |
Unknown |
2025-12-31 |
2024-03-08 |
Treatments |
|
ChiCTR2300070364 |
ChiCTR2300070364 | N/A |
Recruiting |
Drug Hypersensitivity |
2024-03-26 |
2023-06-09 |
Treatments |
|
ChiCTR-IOR-15007571 |
ChiCTR-IOR-15007571 | N/A |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2016-03-01 |
|||
ChiCTR-ONC-13003067 |
ChiCTR-ONC-13003067 | N/A |
Completed |
Chronic Cough |
2015-03-31 |
|||
ChiCTR-TRC-08000152 |
ChiCTR-TRC-08000152 | N/A |
Completed |
Chronic Cough |
2009-06-30 |
